EGFL6 and neoplasm: To evaluate the role of myeloid cells in Egfl6-driven tumor progression, 2F8c+/– Egfl6 or ID8+/– Egfl6 tumor-bearing mice were treated with IgG control or a-Ly6G/Ly6C antibody (Ab).